Coronary heart disease combined with heart failure
Conditions
Interventions
Trial group:Conventional treatment + Guanxin Ning tablets
Control group:Routine treatment
Sponsors
Xiuyan Manchu Autonomous County People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. meet the diagnostic criteria for coronary heart disease 2. meet the diagnostic criteria for chronic heart failure; 3. be between 18 and 80 years of age both male and female; 4.Voluntarily participate in this trial and sign an informed consent form
Exclusion criteria
Exclusion criteria: 1. severe primary hypertension (seated systolic blood pressure >= 180 mmHg and/or seated diastolic blood pressure >= 110 mmHg) but poorly controlled by medication malignant hypertension hypertensive emergencies hypertensive crises and hypertensive encephalopathy; known secondary hypertension; 2. Admission to the hospital for exacerbation of heart failure within 4 weeks before enrollment and confirmed by records; myocardial infarction or coronary artery revascularization within 2 months before enrollment; paroxysmal atrial fibrillation persistent atrial fibrillation persistent atrial fibrillation for more than 1 year within 4 weeks before enrollment and the condition of the above three kinds of atrial fibrillation is still not stabilized after treatment permanent atrial fibrillation or atrial flutter; 3. Combination of other heart diseases: pulmonary heart disease pre-coronary heart disease moderate to severe pulmonary hypertension moderate to severe stenosis or closure insufficiency of heart valves cardiomyopathy and patients with heart failure caused by cardiac arrhythmia; episodes of tachycardia (except for sinus tachycardia) or cardiogenic shock unstable angina pectoris and the presence of uncontrollable malignant cardiac arrhythmia; those who have undergone cardiothoracic surgery (except for those who have had coronary artery bypass grafting surgery) and those who have a subject with planned to undergo left ventricular remodeling surgery history of previous heart transplantation or planned heart transplantation; 4. active tuberculosis; 5. autoimmune diseases such as systemic lupus erythematosus giant cell myocarditis; 6. Serious diseases affecting their survival (e.g. tumors etc.) and psychiatric illnesses with poor control and drug addicts who are not detoxified; 7. Excessive obesity body mass index (BMI) > 30kg/m^2; 8. Serious hepatic and renal dysfunction; GFR<=30ml/(min-1.73m^2)); 9. use of other blood-activating and blood-stasis-removing traditional Chinese medicines with specific combinations based on the actual clinical needs of the investigator; 10. Patients with known allergy to the study drug (including its constituent ingredients); 11. Those with pregnancy plan or pregnant or lactating women or those who cannot guarantee effective contraception during the trial period; 12. patients who have participated in other clinical trials within the last 3 months; 13.Patients who in the opinion of the investigator have factors that make them unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| echocardiography; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum non-targeted metabolomics;Six-minute walk test;N-terminal pro-B-type natriuretic peptide;Angina symptom score;Fecal 16s rDNA/Metagenomics;New York Heart Association Functional Classification; | — |
Countries
China
Contacts
Public ContactWang Yu
Xiuyan Manchu Autonomous County Central People's Hospital
Outcome results
None listed